Background: Chronic fatigue (CF) has been reported to be slightly more prevalent in testicular cancer survivors (TCSs) than in the general population. In this study, we wished to explore possible determinants of CF in TCSs median 12 (survey I) and 19 years (survey II) after treatment, in particular the relation to late effects after treatment.
with age in the general male population (from 9.6% to 12.2% for the decadal age groups 40-49 and 50-59, respectively) [15] . Currently, little is known about the longitudinal development of CF in cancer survivors and a relevant question is whether the observed increase of CF in the general population will be more or possibly less pronounced in TCSs. Anxiety, depression, and comorbidity have been shown to be associated with CF, whereas other factors associated with fatigue have rarely been assessed in TCSs, and to our knowledge not with follow-up data up to 20 years after treatment [14] .
The number of cancer survivors referred due to CF to the Norwegian Advisory Unit on Late Effects after Cancer Treatment has been increasing and includes TCSs with debut of CF several years after treatment. Intrigued by this observation, we wished to assess the prevalence of CF and its possible determinants in TCSs after longer time of observation than previous reports [14] , and in particular assess CF in relation to the comorbidity and toxicities commonly observed in TCSs like CVD, anxiety, depression, hypogonadism, and neurotoxicity [4] .
Aims of this explorative study were: (i) to describe the prevalence of CF in a population-based cohort of TCSs at two late time points after treatment, (ii) to assess the relationship between CF and possible risk factors including serum levels of testosterone and LH, treatment type, long-term toxicities, depression, anxiety, and comorbidities.
methods design and study population
This longitudinal study originates from two national population-based surveys conducted during 1998-2002 (SI) and -2008 , assessing somatic and psychosocial health in long-term TCSs. All men aged 18-75 years treated for unilateral germ cell TC in Norway from 1980 through 1994 were invited (n = 1814, SI). Exclusion criteria were: extragonadal germ cell cancer or secondary malignancies except skin cancer, bilateral orchiectomy, or mental retardation. Treatment details for TCSs during the study period have been described previously [16] .
A total of 1463 males (81%) participated at SI. However, exclusion of those with missing hormone samples, questionnaire data, and other reasons resulted in 812 men eligible at both surveys ( Figure 1 ).
At SI, median 12 years (range 5-21 years) after TC treatment, participants underwent a clinical examination. Serum for hormone analyses was generally collected before 11 a.m. SII was carried out at median 19 years (range 13-28 years) after treatment, and blood samples were collected before 12 noon at the primary care physician's office, and all samples were sent to central analysis.
At SI and SII, the participants completed a questionnaire including the Fatigue Questionnaire (FQ), the Scale for Chemotherapy-Induced Neurotoxicity (SCIN), and questions addressing comorbidities, medication, tobacco use, and marital status [17, 18] .
Both surveys were approved by the Regional Committee for medical and health research ethics of the South Eastern Health Region in Norway.
questionnaires
The FQ includes 11 items (7 items covering physical fatigue and 4 items covering mental fatigue) [18, 19] . Each item has four response alternatives (0-3). Summation of the 11-item scores yields a total fatigue score between 0 and 33, with higher scores indicating higher levels of fatigue. Two additional questions evaluate the extent and duration of fatigue (less than a week = 0, less than 3 months = 1, between 3 and 6 months = 2, and more than 6 months = 3). For case definition, the 11-item scores were dichotomized (0 and 1 = 0, and 2 and 3 = 1) and summarized, with a sum score of ≥4 and duration of symptoms ≥6 months defining CF [13, 20] .
The Hospital Anxiety and Depression Scale (HADS) consists of 7 items covering anxiety (HADS-A) and 7 items covering depression (HADS-D), with item scores of 0-3. Total sum scores (0-21) are calculated by summation of 7-item scores, with higher scores indicating higher symptom levels, and with scores of 8 or above defining caseness of both HADS-A and HADS-D [21] .
Comorbidity was recorded based on self-reported diabetes, cardiac disease (incident angina or heart attack), or pulmonary disease (yes/no).
Levels of physical activity were categorized into three groups (inactive, moderately active, and highly active) as previously published [22] .
Neurotoxicity was assessed by the SCIN [17] . The TCSs responded to how bothered they were (not at all = 0, a little = 1, quite a bit = 2, and very much = 3), by each of the six symptoms (neuropathy in hands/fingers and/ or feet/toes, Raynaud's phenomenon in hands/fingers and/or feet/toes, tinnitus, and/or reduced hearing). To reduce the number of variables in the multivariate analyses, the two questions regarding neuropathy (hands/ fingers and feet/toes) were combined into one item, recording the worst score for any of these two symptoms with corresponding procedures for Raynaud's phenomenon and ototoxicity.
laboratory analyses
Testosterone and LH levels were measured at both surveys by routine immunoassays. During the study period, the laboratory changed the analytic method. However, for both testosterone and LH, the correlations between assays were within biological variations. Cross-reactivity between LH and human chorionic gonadotropin was minimal.
The reference intervals reported by Bjerner et al. were used for both study periods [23] . Testosterone and LH levels from TCSs were categorized into quartiles according to the cutoff values for the 25, 50, and 75 percentiles of the reference intervals for each decadal age group, thereby adjusting for agerelated variations, as previously published [5] . This categorization yields more information than a dichotomization according to cutoff levels.
statistical methods
Crude associations between continuous variables were assessed with paired t-tests and with χ 2 -test for trend for ordered categorical variables. Additional univariate logistic regression analyses were carried out to evaluate associations between CF and testosterone levels, LH levels, and treatment. Age was not linear in the logit, moreover, when entered as decades it was not statistically significant and therefore not included into the final model in order to save statistical power.
When selecting the best final model, we used the objective criteria, the Akaike information criterion (AIC), and our clinical knowledge. Our modeling process focused on variables that were both of clinical interest and statistically significantly associated with the dependent variable. We have tried several models and chose to present the one with the smallest AIC [24] . We did not use any automated variable selection methods like backward or forward selection because the number of possible covariates and models was rather limited.
Multivariate logistic regression analyses were carried out to investigate the associations between CF at SI and SII separately, and hormone levels, type of treatment, neurotoxicity, and comorbid conditions. Variables considered of high clinical relevance (e.g. treatment), and variables associated with CF (P ≤ 0.05) in the univariate analyses, were included in the multivariate analyses.
All tests were two-sided, and P-values ≤0.05 were considered statistically significant. Our analyses were considered exploratory, so adjustment for 
patients' characteristics
Of the 812 TCSs included, 29% had a metastatic disease at diagnosis (Table 1 ). In total, 164 men (20%) had been treated with surgery alone, whereas 343 men (42%) received radiotherapy and 305 (38%) received chemotherapy. In the latter group, 32 males had also received radiotherapy. Median age at SII was 50 years in the surgery and chemotherapy group, and 55 years in the radiotherapy group. Testosterone substitution was initiated in 19 men between the surveys, due to contralateral TC in 7. These 19 men were excluded from all analyses at SII.
Participants and non-participants did not differ with regard to age, stage, and treatment type.
prevalence of CF and comparisons between TCSs with CF at SII only, or at both surveys At SI, 126 males (15%) had CF, whereas at SII, 215 TCSs (27%) had CF. Two-thirds (n = 85) of the 126 TCSs with CF at SI were also classified with CF at SII, whereas there were 130 new cases of CF at SII. Univariate analyses comparing those with CF at SII only and those with CF at both surveys for all variables did not reveal any significant differences, except for a significantly higher mean score at SII for total fatigue (21.0, P = 0.005) and HADS-A (7.4, P = 0.012) and for TCSs having CF at both surveys. Table 2 ). At SII, a low educational level, ever-smoking, physical inactivity, diabetes, cardiac disease, and pulmonary disease were also significantly associated with CF. In total, 21%, 30%, and 28% of those treated by surgery, radiotherapy, or chemotherapy, respectively, reported CF at SII. Logistic regression analyses assessing associations between treatment groups or ageadjusted hormone levels with CF revealed that radiotherapy, but not chemotherapy, was associated with an increased risk of CF at SII when compared with surgery only (P = 0.028 and 0.106, respectively). Furthermore, having testosterone in the lowest versus the highest quartile was associated with an increased risk of CF (P = 0.023), while no significant associations emerged for LH levels (data not shown). Age was not significantly associated with CF at any of the surveys (Table 2 ). There were no significant associations between CF and hormone levels at SI. multivariate analyses. At SI, TCSs with higher levels of anxiety and depression had a roughly three-fold increased risk of CF compared with those with lower levels of anxiety and depression, whereas those with the highest level of neuropathy, and the second highest level of tinnitus/decreased hearing, had roughly two-to three-fold increased risks of CF compared with those with none of these symptoms (Table 3) . No other significant associations emerged at SI.
At SII, TCSs being moderately or highly physically active had a protective effect against CF compared with those being inactive (reference), with ORs of 0.47 and 0.31 (95% CI 0.25-0.87 and 0.17-0.60, respectively). TCSs with testosterone in the lowest and second highest quartile had significantly elevated risks of CF when compared with TCSs with testosterone in the highest quartile (ORs of 3.2 and 2.6, respectively), and testosterone levels in the second quartile had a similar OR of 2.2, but did not reach statistical significance (Table 3 ). There was a stepwise increase in the risk of CF with increasing levels of neuropathy with OR of 3.4 (95% CI 1.7-7.0) for the highest level compared with no neuropathy. The highest level of Raynaud's phenomenon was significantly associated with a higher risk of CF with an OR of 2.4. No significant associations emerged for CF and tinnitus/reduced hearing. Prevalent cardiac disease displayed borderline significant risk for CF with OR of 1.9 (95% CI 0.9-3.7), compared with no cardiac disease (P = 0.08).
CF was not significantly associated with the level of education, smoking, diabetes, pulmonary disease, age, or treatment. Sensitivity analyses when excluding the 32 males who received both radiotherapy and chemotherapy did not change our results, indicating robust associations and no major impact from the combination of radiotherapy and chemotherapy on CF.
discussion
On the background of a 10% prevalence of CF in the Norwegian general male population [15] , the increasing prevalence of CF in TCSs from 15% after 12 years to 27% 19 years after treatment is remarkable and might have ramifications for long-term cancer survivors in general. Two-thirds of those with CF at SI also had CF at SII. Those with CF at both surveys had significantly higher total fatigue scores and anxiety levels than those only having CF at SII.
In univariate analyses at SI, only few of the examined covariates were associated with CF (all three symptoms assessed by the SCIN and the score of HADS-A and HADS-D). At SII, however, most of the 17 variables examined were significantly associated with CF.
Also in the multivariate analysis, an increase of variables associated with CF from SI to SII became apparent. Results from SI should, however, be interpreted with caution due to the low number of disease events at this time point. Higher levels of anxiety, depression, and neurotoxicity (neuropathy and Raynaud's phenomenon) and lower quartiles of testosterone were all significantly associated with CF at SII, whereas moderate and high physical activity had a protective effect. The increase in factors associated with CF accompanying an increase in the prevalence of fatigue might represent a shared development: reduced stress coping. Presumably, TCSs being fatigued will be less able to filter out the stress from, e.g. neuropathy in fingers or toes. On the other hand, chronic neuropathy might tire out cancer survivors, finally resulting in fatigue. Apparently, the development of CF is a slow process in the relatively young TCSs, as it took up to two decades until about one of the four TCSs reported CF. Prior radiotherapy was significantly associated with CF at SII in univariate (logistic regression), but not in the multivariate analysis. Possibly, late effects known to be associated with radiotherapy (e.g. hypogonadism, diabetes, CVD, and neuropathy), and aging competed with radiotherapy itself as risk factors for CF [4] . This may, to some extent, have contributed to the different proportions of CF after radiotherapy and surgery of 30% versus 21%, respectively. The lack of significant associations between CF and types of treatment, but with treatment-related toxicities and self-reported comorbidity, is in accordance with the majority of studies on CF in cancer survivors [25] [26] [27] . Fewer TC patients are currently treated with radiotherapy than during the study period, and modern radiation techniques, reduced volumes, and target doses will probably render radiotherapyinduced side-effects a less prominent problem among future TCSs.
The risk of CF was significantly decreased for moderately and highly active men when compared with those reporting being inactive at SII. Whether CF results in inactivity, and/or inactivity contributes to the development of fatigue, is still open for discussion. However, fatigue after cancer treatment may be reduced by initiating or maintaining adequate levels of physical activity according to meta-analyses, systematic reviews, and randomized trials [28] . Contributing factors (e.g. medical and substanceinduced) should be assessed and treated in cancer survivors with moderate to severe fatigue, before intervening through physical activity programs.
Low testosterone levels were significantly associated with CF at SII. Importantly, the majority of TCSs (428 of the 793) had testosterone levels in the lowest quartile, rendering this the strength of this association more important than the borderline association between CF and more normal testosterone levels.
This finding contrasts with Huddart et al., who found no significant relationship between testosterone and fatigue in TCSs, possibly due to a shorter follow-up time. Different categorizations of testosterone in the two studies (levels below 10 nmol/l versus ordinal categorization according to quartile thresholds for decadal age groups) might also have contributed to the varying results. Importantly, our observations do not imply testosterone substitution as a means to treat chronic-fatigued in general, but rather that high testosterone levels are associated with the absence of CF. Nevertheless, as testosterone replacement in a study of severely hypogonadal males yielded increased energy levels, such treatment may be considered in fatigued TCSs with consistently low testosterone levels [29] .
Strengths of our study comprise the large population-based and well-characterized cohort of TCSs, and the longitudinal study design. Blood samples were collected at relatively consistent diurnal time points, with available hormone levels and the FQ for 812 men. Detailed information regarding previous cancer treatment was available through collaboration between the five University hospitals in Norway, with all TCSs treated according to the international guidelines. High participation rates of roughly 80% at both surveys imply validity of our findings and render selection bias less likely, although the rigorous selection including only those with complete blood samples and questionnaires at both surveys reduced the number of eligible men to 812. Hormone levels represent the only objective measure in this study, and reliance on subjective factors might be considered a limitation. However, CF is not objectively measurable, and self-reported comorbidity might actually better represent the impact on CF than physiological assessments of cardiac or pulmonary function [17, 30] . The lack of assessment of CF before treatment poses a limitation as we cannot assess a potential impact of TC treatment on CF before SI.
In conclusion, this longitudinal study reveals a substantial increase in CF during 12-19 years after treatment, with higher levels of anxiety, depression, and neurotoxicity, and lower levels of testosterone, being associated with CF at the second assessment. Moderate and high physical activity indicated a protective effect. These findings indicate means to prevent or treat CF. Health-care professionals should have early prevention of CF through lifestyle interventions and early detection, and treatment and follow-up of comorbid conditions in mind when caring for TCSs and probably other cancer survivors as well. Testosterone substitution may be considered in order to ameliorate or treat CF in hypogonadal males after repeated testosterone evaluations. CF may dramatically impair quality of life, and its disturbing increase in TCSs and the association with partly treatable side-effects emphasizes the importance of continued long-term assessments of cancer survivors.
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